Changes in Patterns of Use of Advanced Therapies Following Emerging Data About Adverse Events in Patients With Rheumatoid Arthritis From the Veterans Affairs Health System
Abstract
To determine whether prescribing practices for Janus kinase inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), and non‐TNFi biologic agents changed after the results of the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance trial were released in January 2021.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2023
- Source ID
- 10.1002/acr2.11602
Entities
People
- Brian C Sauer
- Bryant R England
- Grant W Cannon
- Joshua F Baker
- Michael George
- Stephanie Jeong
- Ted R Mikuls
Organizations
- National Institute of General Medical Sciences
- National Institutes of Health
- Rehabilitation Research and Development Service
- United States Department of Defense
- United States Department of Veterans Affairs
- University of Nebraska Medical Center
- University of Pennsylvania
- University of Utah